

Form PTO-1449 U.S. Department of Commerce  
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.

A34060-A-A (090495.0285)

Serial No.

10/790,266

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(Use several sheets if necessary)

Applicant

De Brabander et al.

Filing Date

March 1, 2004

Group

1625

**U.S. PATENT DOCUMENTS**

*Exam. Init	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
	5 9 3 6 1 0 0	8/10/99	Fürstner et al.			

**FOREIGN PATENT DOCUMENT**

	Document No.	Date	Country	Class	SubClass	Translator Yes No
	0 0 5 1 5 8 9	9 Aug. 2000	WIPO			
	9 9 0 5 1 3 6	4 Feb. 1999	WIPO			
	9 9 4 7 5 2 3	23 Sept. 1999	WIPO			

**OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)**

	Boyd MR, Farina C, Belfiore P, Gagliardi S, Kim JW, Hayakawa Y, Beutler JA, McKee TC, Bowman BJ, Bowman EJ (2001). Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H <sup>+</sup> )-ATPases. <i>J. Pharmacol. Exp. Ther.</i> 297(1):114-120.
	Jansen R, Kunze B, Reichenbach H, Höfle G (2000). Antibiotics from gliding bacteria, LXXXVI. Apicularen A and B, cytotoxic 10-membered lactones with a novel mechanism of action from <i>Chondromyces</i> species (Myxobacteria): isolation, structure elucidation, and biosynthesis. <i>Eur. J. Org. Chem.</i> 2000:913-919.
	Snider BB, Song F (2000). Synthesis of the N-((1E)-alkenyl)-(2Z,4Z)-heptadienamide side chain of salicylihalamide A and apicularens A and B. <i>Org. Lett.</i> 2(3):407-408.
	Ackermann L, Fürstner A, Weskamp T, Kohl FJ, Herrmann WA (1999). Ruthenium carbene complexes with imidazolin-2-ylidene ligands allow the formation of tetrasubstituted cycloalkenes by RCM. <i>Tet. Lett.</i> 40:4787-4790.
	Huang J, Stevens ED, Nolan SP, Petersen JL (1999). Olefin metathesis-active ruthenium complexes bearing a nucleophilic carbene ligand. <i>J. Am. Chem. Soc.</i> 121:2674-2678.

NY02:488108.1

Examiner

Date Considered

8/20/2004

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce  
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.  
A34060-A-A (090495.0285)

Serial No.  
10/790,266

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(Use several sheets if necessary)

Applicant  
De Brabander et al.

Filing Date  
March 1, 2004

Group  
1625

69 Scholl M, Trnka TM, Morgan JP, Grubbs RH (1999). Increased ring closing metathesis activity of ruthenium-based olefin metathesis catalysts coordinated with imidazolin-2-ylidene ligands *Tet. Lett.* 40:2247-2250.

69 Kunze B, Jansen R, Sasse F, Höfle G, Reichenbach H (1998). Apicularens A and B, new cytostatic macrolides from *Chondromyces* species (Myxobacteria): production, physico-chemical and biological properties. *J. Antibiot. (Tokyo)* 51(12):1075-1080.

69 McKee TC, Galinis DL, Pannell LK, Cardellina II JH, Laasko J, Ireland CM, Murray L, Capon RJ, Boyd MR (1998). The lobatamides, novel cytotoxic macrolides from Southwestern Pacific tunicates. *J. Org. Chem.* 63:7805-7810.

69 Erickson KL, Beutler JA, Cardellina II JH, Boyd MR (1997). Salicylihalamides A and B, novel cytotoxic macrolides from the marine sponge *Haliclona* sp. *J. Org. Chem.* 62:8188-8192.

69 Crider BP, Xie XS, Stone DK (1994). Bafilomycin inhibits proton flow through the H<sup>+</sup> channel of vacuolar proton pumps. *J. Biol. Chem.* 269(26):17379-17381.

69 Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Meth.* 65(1-2):55-63.

69 Still WC, Kahn M, Mitra A (1978). Rapid chromatographic technique for preparative separations with moderate resolution. *J. Org. Chem.* 43:2923-2925.

NY02:488108.1

Examiner

*Antoine*

Date Considered

*8/20/2004*

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.